Lv61
2780 积分 2021-06-10 加入
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
7天前
已完结
自体富血小板血浆制备技术专家共识
21天前
已完结
Spatial profiling of METex14-altered NSCLC under tepotinib treatment: Shifting the immunosuppressive landscape
1个月前
已完结
Savolitinib in NSCLC: progress in the MET exon 14 journey
1个月前
已完结
Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study
1个月前
已完结
Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
1个月前
已完结
Artificial intelligence in the early stages of drug discovery
1个月前
已完结
Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study
2个月前
已完结
Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study
2个月前
已完结
Efficacy and safety of KRAS G12C inhibitor IBI351 monotherapy in patients with advanced non-small cell lung cancer: results from a phase 2 pivotal study
2个月前
已完结
皖公网安备34019202002308
